Logo

BioMérieux

BioMérieux Receives CE Mark for Vitek Clinical Microbiology Mass Spec System

The company said it plans to launch the instrument in selected European and Asian markets in the second half of 2021, with a global launch planned for 2022.

BioMérieux Reports 10 Percent Q1 Revenue Growth, Lowers Full-Year Guidance

The firm now guides for neutral to mid-single digit growth in 2021, decreased from a prior range of 5 percent to 8 percent growth.

BioFire Dx Receives First FDA Marketing Clearance for SARS-CoV-2 Respiratory Panel

The test is the first COVID-19 assay to transition from Emergency Use Authorization to a cleared regulatory status.

BioMérieux Reports 21 Percent Revenue Growth in Q4

The firm guided for 2021 revenue growth of between 5 percent and 8 percent, citing "a persistently uncertain business environment."

In Brief This Week: Natera, Sync for Genes, Castle Biosciences, BioMérieux, PathogenDx, More

News items for the week of Dec. 21, 2020.

Dec 16, 2020

BioMérieux Nabs CE Mark for RT-PCR SARS-CoV-2, Influenza A/B Assay

Dec 8, 2020

BioMérieux Coronavirus Test Gets FDA OK for Use With Pooled Samples

Oct 22, 2020

BioMérieux Q3 Revenues Increase 21 Percent

Sep 8, 2020

As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza
Premium

Sep 2, 2020

BioMérieux Posts 16 Percent Sales Growth for First Half of 2020

Jul 21, 2020

AdvaMed Partners With Dx Companies to Create National COVID-19 Supply Registry

Jul 15, 2020

BioMérieux BioFire Respiratory Panel With SARS-CoV-2 Target Nabs CE Mark

Jul 9, 2020

BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

May 19, 2020

BioMérieux's BioFire Pneumonia Panel Could Improve Care, Find Secondary Infection in COVID-19 Cases
Premium

May 8, 2020

BioMérieux Gets US Emergency Use Authorization for SARS-CoV-2 R-Gene MDx

May 4, 2020

BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA Emergency Use Authorization

Apr 16, 2020

BioMérieux Reports 22 Percent Q1 Revenue Growth, Withdraws Full-Year Guidance

Mar 24, 2020

BioMérieux Rapid Coronavirus Test Gets FDA Emergency Use Authorization

Mar 20, 2020

Commercial Coronavirus Test Developers Tweak Timelines, EUA Plans in Light of Loosened FDA Guidance

Mar 12, 2020

Jury Rules in Favor of Hologic, Grifols in BioMérieux Patent Infringement Lawsuit

Mar 12, 2020

DIAMONDS Project Using New Classification Approach to Develop Rapid Infectious Disease Tests
Premium

Feb 26, 2020

BioMérieux Reports 11 Percent Revenue Growth in Q4

Jan 14, 2020

BioMérieux Submits 43-Target BCID2 Test to FDA

Jan 10, 2020

The Decade In Proteomics: Most Significant New Applications
Premium

Oct 22, 2019

BioMérieux Q3 Revenues Up 13 Percent

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.